- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06303661
Non-ablative Radiofrequency and Low Intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease
March 4, 2024 updated by: Centro de Atenção ao Assoalho Pélvico
Non-ablative Radiofrequency and Low-intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease: Case Series
The goal of this one arm clinical trial is to evaluate the safety and describe the clinical response of non-ablative radiofrequency treatment associated with shockwave therapy in men with Peyronie's disease.
The main question[s] it aims to answer are: • is the treatment safe?
• is there any clinical response to the proposed treatment?
Participants will respond to five validated questionnaires: International Index of Erectile Dysfunction (IIEF-5), Medical Outcomes Study 36 - Item Short - Form Health Survey (SF-36), Peyronie's Disease Questionnaire (PDQ), Scale Hospital for Anxiety and Depression (SHAD) and the Erection Quality Questionnaire (EQQ); will undergo a physical assessment that includes palpation of the fibrotic plaque on the penis, pharmacological induction of erection, and assessment of the size of the fibrotic plaque through ultrasound.
Every five sessions, the participant's degree of satisfaction will be measured using a 5-point Likert scale, as well as the evolution of symptoms will also be observed, using a 10-point Visual Analogue Scale (VAS) and penile pain, if present.
The entire evaluation protocol will be applied before (pre-test), after treatment (post-test) and 1 month after the end of treatment.
Volunteers will be monitored by telephone to verify the long-term response after 3, 6, 9 and 12 months of completed treatment in relation to the Likert scale and VAS.
The treatments they'll be given are • of monopolar non-ablative radiofrequency associated with • low-intensity shock wave therapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carlos Mamede, doctorade
- Phone Number: 55 71 996673967
- Email: carlosmamede@bahiana.edu.br
Study Contact Backup
- Name: Patrícia Lordelo, post-PhD
- Phone Number: 55 71 996592400
- Email: pvslordelo@hotmail.com
Study Locations
-
-
Ba
-
Salvador, Ba, Brazil, 40.290-000
- Recruiting
- Centro de Atenção ao assoalho pélvico
-
Principal Investigator:
- Patricia V Lordelo, Phd
-
Contact:
- Patricia V Lordelo, Phd
- Phone Number: +5571988592400
- Email: pvslordelo@hotmail.com
-
Sub-Investigator:
- Carlos Mamede, Phd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Clinical complaint related to Peyronie's disease;
- At any stage of the disease (acute or chronic).
Exclusion Criteria:
- Users of a pacemaker, cardiac defibrillator implant or any other electromagnetic implant;
- Metallic implants over or under the area to be treated.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RF and SWT
The treatment will be carried out through the application of monopolar non-ablative radiofrequency (IBRAMED, Amparo, São Paulo, Brazil - model NÈARTEK) associated with electromagnetic low-intensity shock wave therapy (IBRAMED, Amparo, São Paulo, Brazil - model THORK) on the fibrotic plaque in the penis, 2 to 5 times a week, according to the patient's availability, totaling 24 sessions.
|
There are two electrodes: one active, which will be used on the penis, using a non-lubricated condom from the Blowtex brand, using pharmaceutical glycerin to emit radiofrequency inside and outside the condom, and another electrode, dispersive, wrapped in PVC-type plastic film, coupled to the region of the patient's penis where there is no fibrotic plaque, which will act as earth and the temperature to be used in the treatment will be 38°C.
When the desired heating is reached, the device maintains the temperature and thus the radiofrequency application will be maintained for 2 minutes.
The equipment's applicator is covered with transparent PVC film and non-alcoholic gel is used as a coupling medium between the applicator and the penis.
The following parameters are used: frequency of 10Hz, energy of 120mJ and 2,000 shots in the fibrotic plaque.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
It is estimated that non-ablative RF associated with low-intensity SWT in patients with Peyronie Disease is a safe technique that leads to a satisfactory clinical response in relation to sexual function.
Time Frame: From enrollment to the end of treatment till 8 weeks, then after 1, 3, 6, 9 and 12 months.
|
It will be measured by the questionnaire International Index of Erectile Dysfunction (IIEF-5).
Lower values represent worse sexual function and are categorized as follows: 5-7 points represents severe erectile dysfunction, 8-11 points represents moderate erectile dysfunction, 12-16 represents mild to moderate erectile dysfunction, 17 -21 represents mild erectile dysfunction and 22-25 means no erectile dysfunction.
|
From enrollment to the end of treatment till 8 weeks, then after 1, 3, 6, 9 and 12 months.
|
It is estimated that non-ablative RF associated with low-intensity SWT in patients with Peyronie Disease is a safe technique that leads to a satisfactory clinical response in relation to pain.
Time Frame: From enrollment to the end of treatment till 8 weeks, then after 1, 3, 6, 9 and 12 months.
|
The level of pain will be assess by the question three questions of Peyronie's Disease Questionnaire (PDQ).
Each of the three questions score from 0 to 10, so the total range will be from 0 to 30.
The lower the score, the less pain the patient feels.
|
From enrollment to the end of treatment till 8 weeks, then after 1, 3, 6, 9 and 12 months.
|
It is estimated that non-ablative RF associated with low-intensity SWT in patients with Peyronie Disease is a safe technique that leads to a satisfactory clinical response in relation to penile erection.
Time Frame: From enrollment to the end of treatment till 8 weeks, then after 1, 3, 6, 9 and 12 months.
|
The quality of penile erection will be measured by the Quality of Erection Questionnaire.
The final score can vary between 0 and 100 points, with the higher the score, the better the quality of the erection.
|
From enrollment to the end of treatment till 8 weeks, then after 1, 3, 6, 9 and 12 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
It is estimated that non-ablative RF associated with low-intensity SWT in patients with Peyronie Disease is a technique that promotes a positive impact on quality of life and psycho-emotional aspects of anxiety and depression.
Time Frame: From enrollment to the end of treatment till 8 weeks, then after 1, 3, 6, 9 and 12 months.
|
It will be measured by the questionnaire Medical Outcomes Study 36 - Item Short - Form Health Survey (SF-36).
The final score for each domain ranges from 0 to 100 (there are two - body and mental), there is no cutoff point and higher scores indicate a better health status.
|
From enrollment to the end of treatment till 8 weeks, then after 1, 3, 6, 9 and 12 months.
|
It is estimated that non-ablative RF associated with low-intensity SWT in patients with Peyronie Disease is a technique that promotes a positive impact on psycho-emotional aspects of anxiety and depression.
Time Frame: From enrollment to the end of treatment till 8 weeks, then after 1, 3, 6, 9 and 12 months.
|
It will be measured by the questionnaire Scale Hospital for Anxiety and Depression.
It is composed of two subscales, one for anxiety and the other for depression, with seven items each.
The global score on each subscale ranges from 0 to 21.
The lower the score, the lower level of anxiety/or depression.
|
From enrollment to the end of treatment till 8 weeks, then after 1, 3, 6, 9 and 12 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 8, 2024
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
December 4, 2023
First Submitted That Met QC Criteria
March 4, 2024
First Posted (Actual)
March 12, 2024
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 4, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 74001323.3.0000.5544
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peyronie Disease
-
Hopital FochDornier MedTech SystemsRecruitingPenile Diseases | Peyronie DiseaseFrance
-
King's College LondonCompletedPeyronie DiseaseUnited Kingdom
-
Odense University HospitalUnknown
-
University Hospital, MontpellierCompletedPeyronie DiseaseFrance
-
University Hospital, ToulouseRecruitingPeyronie DiseaseFrance
-
University of Roma La SapienzaRecruitingPeyronie DiseaseItaly
-
University of MiamiEndo PharmaceuticalsCompleted
-
Mayo ClinicActive, not recruiting
-
IBSA Farmaceutici Italia SrlActive, not recruiting
-
Man Clinic for Andrology, Male Infertility and...UnknownErectile Dysfunction | Peyronie' DiseaseEgypt
Clinical Trials on Non-ablative Radiofrequency
-
Centro de Atenção ao Assoalho PélvicoRecruitingGenitourinary Syndrome of MenopauseBrazil
-
Centro de Atenção ao Assoalho PélvicoCompleted
-
Fundació d'investigació Sanitària de les Illes...University of the Balearic IslandsNot yet recruitingPelvic Organ Prolapse
-
University of Kansas Medical CenterRecruitingNon-small Cell Lung CancerUnited States
-
Bispebjerg HospitalCompleted
-
Massachusetts General HospitalUnknown
-
Montefiore Medical CenterScitonRecruitingAndrogenetic Alopecia | Scarring AlopeciaUnited States
-
The Cleveland ClinicTerminatedAbdominoplasty ScarsUnited States
-
Escola Bahiana de Medicina e Saude PublicaUnknown